{"name":"Phoenix Neurological Associates, LTD","slug":"phoenix-neurological-associates-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Zinc and Copper","genericName":"Zinc and Copper","slug":"zinc-and-copper","indication":"Zinc and copper deficiency in neurological conditions","status":"marketed"}]}],"pipeline":[{"name":"Zinc and Copper","genericName":"Zinc and Copper","slug":"zinc-and-copper","phase":"marketed","mechanism":"Zinc and copper act as essential cofactors for metalloenzymes and antioxidant systems, supporting neurological function and reducing oxidative stress.","indications":["Zinc and copper deficiency in neurological conditions","Supportive therapy in neurodegenerative or neurological disorders"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE9nTHYtbTRnMVpuMU9Id25BME83bWo3TGQtYk9LVFo0RXFuZ21zSUR3bzAzMzFTS3dfb2Q0cFdBeVM5bTlZWm9Ydnd3elR3MEUxaHZWQkFldk9IX3gzcTFETU44X1lnR3ZvSnc?oc=5","date":"2023-12-26","type":"pipeline","source":"Neurology® Journals","summary":"Review process for IVIg treatment - Neurology® Journals","headline":"Review process for IVIg treatment - Neurology® Journals","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}